By Ebi Kesiena
Government of Equatorial Guinea has disclosed that two more people in the country have died of Marburg hemorrhagic fever, a cousin of the Ebola virus, bringing the toll of fatalities to 11.
Health Minister Mitoha Ondo’o Ayekaba said in a statement that two days ago, the monitoring system recorded eight notifications, including the deaths of two people with symptoms of the disease.
“Forty-eight contact cases have been documented, four of whom have developed symptoms, and three who have been quarantined in hospital,” it added.
According to him, work is underway to strengthen assessment of the spread of the epidemic.
The Marburg virus is a rare but highly dangerous pathogen that causes severe fever, often accompanied by bleeding and organ failure.
It is part of the so-called filovirus family that also includes the Ebola virus, which has wreaked havoc in several previous outbreaks in Africa.
The central African state announced on February 13 that nine people had died from Marburg between January 7 and February 7.
The U.N.’s World Health Organization (WHO) held an emergency session the following day.
The national authorities have declared a health alert in the remote northeastern province of Kie-Ntem province and in the neighboring district of Mongomo, which are located on the border with Cameroon and Gabon.
Measures include a lockdown plan implemented in collaboration with the WHO.
In their statement of February 13, the authorities had reported only three cases of infection in addition to the fatalities individuals who were being isolated with “mild symptoms” in hospital.
The natural host of the Marburg virus is the African fruit bat, which carries the virus but does not fall sick from it. But the animals can pass the virus to primates in close proximity, including humans, and human-to-human transmission then occurs through contact with blood or other bodily fluids.
There are currently no approved vaccines or antiviral treatments.
Potential treatments, including blood products, immune therapies and drug therapies, as well as early candidate vaccines are being evaluated, the WHO says.
